መነሻ › ትሪፕል-ኔጌቲቭ የደረት ካንሰር › ከንታኪ
በከንታኪ ለትሪፕል-ኔጌቲቭ የደረት ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች
ለትሪፕል-ኔጌቲቭ የደረት ካንሰር የሚደረጉ 6 ጥናቶች በከንታኪ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በከንታኪ ውስጥ ያሉ ከተሞች
Official study text (English)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044), Edgewood
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06393374Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Norton Healthcare, Inc., Louisville
- Mercy Health, Paducah
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT05633654Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- University of Kentucky-Lexington, Lexington
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT05846789Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ጁን 2026 · NCT05005403The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Baptist Health Clinical Research, Elizabethtown
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ27 ኤፕሪ 2022 · NCT05037825ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።